Trump administration announces 15 new drugs for Medicare price negotiation program

U.S. names HIV, arthritis drugs for next Medicare price talks

The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis treatment Xeljanz.

Botox, Trulicity among 15 drugs on new Medicare negotiations list

The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and Trulicity. This third cycle of negotiations is the first to include drugs payable under Medicare Part B, which are traditionally administered in clinical settings, in addition…

Trump administration announces 15 new drugs for Medicare price negotiation program

The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers.

15 new drugs added to Medicare price negotiations

Third round of CMS drug price negotiations target 15 drugs, including Trulicity, Rexulti, Biktarvy, Xolair and Cosentyx. Prices would take effect in 2028.

Medicare will negotiate the price of Botox and 14 other drugs this year

The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations.

CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

Another GLP-1 drug is up for Medicare negotiations under the Inflation Reduction Act. Eli Lilly’s diabetes drug Trulicity is among 15 drugs selected for the third round of negotiations. For the ...